BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Guillebon E, Roussille P, Frouin E, Tougeron D. Anti program death-1/anti program death-ligand 1 in digestive cancers. World J Gastrointest Oncol 2015; 7(8): 95-101 [PMID: 26306141 DOI: 10.4251/wjgo.v7.i8.95]
URL: https://www.wjgnet.com/1948-5204/full/v7/i8/95.htm
Number Citing Articles
1
Guoli Chen, Zhaohai Yang, James R. Eshleman, George J. Netto, Ming-Tseh Lin. Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future PerspectiveBioMed Research International 2016; 2016: 1 doi: 10.1155/2016/9850690
2
André F. Oliveira, Luís Bretes, Irene Furtado. Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal CancerFrontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.00396
3
Julien Taïeb, Thierry André, Farid El Hajbi, Emilie Barbier, Clémence Toullec, Stefano Kim, Olivier Bouche, Frederic Di Fiore, Marion Chauvenet, Hervé Perrier, Ludovic Evesque, Pierre Laurent-Puig, Jean-François Emile, Jérémie Bez, Côme Lepage, David Tougeron. Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trialDigestive and Liver Disease 2021; 53(3): 318 doi: 10.1016/j.dld.2020.11.031
4
Zoran Gatalica, Semir Vranic, Joanne Xiu, Jeffrey Swensen, Sandeep Reddy. High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicineFamilial Cancer 2016; 15(3): 405 doi: 10.1007/s10689-016-9884-6
5
Christine Böger, Hans-Michael Behrens, Micaela Mathiak, Sandra Krüger, Holger Kalthoff, Christoph Röcken. PD-L1 is an independent prognostic predictor in gastric cancer of Western patientsOncotarget 2016; 7(17): 24269 doi: 10.18632/oncotarget.8169
6
Leon Chen, Alexander B. Aria, Sirunya Silapunt, Michael R. Migden. Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin CancerDermatologic Surgery 2019; 45(1): 1 doi: 10.1097/DSS.0000000000001601
7
Paula Baraúna Assumpção, Erika Couto Canelas, Aline Cruz Ramos, Ana Anaissi, João Felipe Acioli, Geraldo Ishak, Sidney Santos, Samia Demachki, Paulo Assumpção. Lymph nodes may be a source for immunetherapy in gastric cancerOncotarget 2020; 11(19): 1729 doi: 10.18632/oncotarget.27578
8
Minyu Wang, Rita A Busuttil, Sharon Pattison, Paul J Neeson, Alex Boussioutas. Immunological battlefield in gastric cancer and role of immunotherapiesWorld Journal of Gastroenterology 2016; 22(28): 6373-6384 doi: 10.3748/wjg.v22.i28.6373
9
Huan Bin Wang, Han Yao, Chu Shu Li, Lun Xi Liang, Yao Zhang, Ying Xuan Chen, Jing-Yuan Fang, Jie Xu. Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapyJournal of Digestive Diseases 2017; 18(10): 574 doi: 10.1111/1751-2980.12538
10
Esmeralda Celia Marginean, Barbara Melosky. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II—The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal CancerArchives of Pathology & Laboratory Medicine 2018; 142(1): 26 doi: 10.5858/arpa.2017-0041-RA
11
Lingyu Li, Wei Li, Chang Wang, Xu Yan, Yizhuo Wang, Chao Niu, Xiaoying Zhang, Min Li, Huimin Tian, Cheng Yao, Haofan Jin, Fujun Han, Dongsheng Xu, Wei Han, Dan Li, Jiuwei Cui. Adoptive transfer of natural killer cells in combination with chemotherapy improves outcomes of patients with locally advanced colon carcinomaCytotherapy 2018; 20(1): 134 doi: 10.1016/j.jcyt.2017.09.009
12
Hamzah Abu-Sbeih, Yinghong Wang. ImmunotherapyAdvances in Experimental Medicine and Biology 2020; 1244: 247 doi: 10.1007/978-3-030-41008-7_12
13
Ye Hong, Zhen-Yu Ding. PD-1 Inhibitors in the Advanced Esophageal CancerFrontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.01418
14
Petra Hudler, Radovan Komel. Gastric Cancer2017;  doi: 10.5772/intechopen.69775
15
L Liu, Y Wang, R Bai, K Yang, Z Tian. MiR-186 inhibited aerobic glycolysis in gastric cancer via HIF-1α regulationOncogenesis 2016; 5(5): e224 doi: 10.1038/oncsis.2016.35
16
James W.T. Toh, Paul de Souza, Stephanie H. Lim, Puneet Singh, Wei Chua, Weng Ng, Kevin J. Spring. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor TherapyClinical Colorectal Cancer 2016; 15(4): 285 doi: 10.1016/j.clcc.2016.07.007
17
Animesh Saurabh, Vandana Raphael, Biswajit Dey, Caleb Harris, Vikas Jagtap, Umesh Das. Expression of PDL1 and Her2neu in Gastric and Gastroesophageal Junction AdenocarcinomaIndian Journal of Surgical Oncology 2021; 12(S1): 144 doi: 10.1007/s13193-020-01245-w
18
Zheyu Song, Yuanyu Wu, Jiebing Yang, Dingquan Yang, Xuedong Fang. Progress in the treatment of advanced gastric cancerTumor Biology 2017; 39(7): 101042831771462 doi: 10.1177/1010428317714626
19
Junhun Cho, Kyoung-Mee Kim, Hee Cheol Kim, Woo Yong Lee, Won ki Kang, Young Suk Park, Sang Yun Ha. The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinomaPathology - Research and Practice 2019; 215(1): 171 doi: 10.1016/j.prp.2018.10.024
20
Naoki Takahashi, Satoru Iwasa, Yusuke Sasaki, Hirokazu Shoji, Yoshitaka Honma, Atsuo Takashima, Natsuko Tsuda Okita, Ken Kato, Tetsuya Hamaguchi, Yasuhide Yamada. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancerJournal of Cancer Research and Clinical Oncology 2016; 142(8): 1727 doi: 10.1007/s00432-016-2184-6
21
Hye Jung Cho, Woo Ram Kim, Joo-Hang Kim, Duk Hwan Kim, Dae Jung Kim, Haeyoun Kang. Colonic Perforation After Treatment With Nivolumab in Esophageal Cancer: A Case ReportAnnals of Coloproctology 2021; 37(Suppl 1): S39 doi: 10.3393/ac.2020.00213.0030
22
Xiaofang Xing, Jianping Guo, Guangyu Ding, Bo Li, Bin Dong, Qin Feng, Shen Li, Jian Zhang, Xiaomin Ying, Xiaojing Cheng, Ting Guo, Hong Du, Ying Hu, Tao Zhou, Xiaohong Wang, Lin Li, Qingda Li, Meng Xie, Liting Li, Xiangyu Gao, Fei Shan, Ziyu Li, Shuqin Jia, Xianzi Wen, Jiping Wang, Jiafu Ji. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patientsOncoImmunology 2018; 7(3): e1356144 doi: 10.1080/2162402X.2017.1356144
23
David J. Birnbaum, François Bertucci, Pascal Finetti, Daniel Birnbaum, Emilie Mamessier. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer 2018; 1869(2): 248 doi: 10.1016/j.bbcan.2018.02.001
24
Ruiqi Liu, Ke Peng, Yiyi Yu, Li Liang, Xiaojing Xu, Wei Li, Shan Yu, Tianshu Liu. Prognostic Value of Immunoscore and PD-L1 Expression in Metastatic Colorectal Cancer Patients with Different RAS Status after Palliative OperationBioMed Research International 2018; 2018: 1 doi: 10.1155/2018/5920608
25
Yun Tian, Hamzah Abu-Sbeih, Yinghong Wang. ImmunotherapyAdvances in Experimental Medicine and Biology 2018; 995: 151 doi: 10.1007/978-3-030-02505-2_7
26
Apostolos Zaravinos, Constantinos Roufas, Majdi Nagara, Beatriz de Lucas Moreno, Maria Oblovatskaya, Christodoulos Efstathiades, Christos Dimopoulos, Georgios D. Ayiomamitis. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancerJournal of Experimental & Clinical Cancer Research 2019; 38(1) doi: 10.1186/s13046-019-1372-z
27
Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal CancerCancers 2019; 11(10): 1567 doi: 10.3390/cancers11101567
28
Giuseppe Ercolano, Maryline Falquet, Giulia Vanoni, Sara Trabanelli, Camilla Jandus. ILC2s: New Actors in Tumor ImmunityFrontiers in Immunology 2019; 10 doi: 10.3389/fimmu.2019.02801
29
Sheik Emambux, Gaelle Tachon, Audelaure Junca, David Tougeron. Results and challenges of immune checkpoint inhibitors in colorectal cancerExpert Opinion on Biological Therapy 2018; 18(5): 561 doi: 10.1080/14712598.2018.1445222
30
Kyung-Ju Kim, Han Kwang Yang, Woo Ho Kim, Gyeong Hoon Kang. Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancersOncotarget 2017; 8(35): 58887 doi: 10.18632/oncotarget.19439
31
Kelly M Wilmas, Quoc-Bao Nguyen, Jigar Patel, Sirunya Silapunt, Michael R Migden. Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspectiveFuture Oncology 2021;  doi: 10.2217/fon-2021-0901
32
Basile Tessier-Cloutier, Steve E. Kalloger, Mohammad Al-Kandari, Katy Milne, Dongxia Gao, Brad H. Nelson, Daniel J. Renouf, Brandon S. Sheffield, David F. Schaeffer. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinomaBMC Cancer 2017; 17(1) doi: 10.1186/s12885-017-3634-5
33
Qingfang Zhao, Liang Cao, Lulu Guan, Liangyu Bie, Saiqi Wang, Bojian Xie, Xiaobing Chen, Xiaokun Shen, Feiling Cao. Immunotherapy for gastric cancer: dilemmas and prospectBriefings in Functional Genomics 2019; 18(2): 107 doi: 10.1093/bfgp/ely019
34
Yajie Zhang, Jingwei Tan, Lu Zhou, Xiaoqing Shan, Jianling Liu, Yong Ma. Synthesis and Application of AS1411-Functionalized Gold Nanoparticles for Targeted Therapy of Gastric CancerACS Omega 2020; 5(48): 31227 doi: 10.1021/acsomega.0c04605
35
Simon Pernot, Toulsie Ramtohul, Julien Taieb. Checkpoint inhibitors and gastrointestinal immune-related adverse eventsCurrent Opinion in Oncology 2016; 28(4): 264 doi: 10.1097/CCO.0000000000000292
36
Shenying Jin, Bo Xu, Lixia Yu, Yao Fu, Hongyan Wu, Xiangshan Fan, Jia Wei, Baorui Liu. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapyOncotarget 2017; 8(24): 38850 doi: 10.18632/oncotarget.16407